Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. EKTERLY® Launch and HAE Focus
KALV logo

KalVista's EKTERLY FDA Approval Ushers in Oral HAE Era with $220M Cash Runway

KALV10-KFiling Date: 7/10/2025
KalVista Pharmaceuticals, Inc.
Description

What this story covers

KalVista's 10-K highlights EKTERLY's FDA approval as the first oral on-demand HAE therapy, backed by KONFIDENT trial data showing 1.8-hour relief. U.S. commercialization ramps up with partnerships in Japan and Canada; FY2025 net loss $183M amid $220M liquidity into 2027. Pipeline eyes Factor XIIa; risks include competition and funding needs.

Story snapshot

CompanyKalVista Pharmaceuticals, Inc.
TickerKALV
VariantStandard detailed
Duration10:43
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000950170-25-095011

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in